November 21, 2026:


Medicare’s first negotiated prices were linked to a $56.63 drop in 30-day out-of-pocket costs for heart drugs with no generic, but only $7.46 for drugs where a generic had already arrived, NYU Grossman School of Medicine researchers reported Nov. 19 in JAMA Network Open. With Medicare Open Enrollment ending Dec. 7, the finding matters to anyone choosing a Part D plan for apixaban (Eliquis), rivaroxaban (Xarelto), empagliflozin (Jardiance), dapagliflozin or sacubitril-valsartan (Entresto).
The estimate for drugs without generics carries a 95% confidence interval of $55.48 to $57.78, and the generic-drug estimate runs from $6.05 to $8.78. Savings with a generic are about 13% of the savings without one. The authors analyzed 6,215 Part D plans, made up of 5,738 Medicare Advantage plans and 477 stand-alone drug plans, using a difference-in-differences design that compares changes for negotiated drugs with changes for comparison drugs.
Negotiated prices for the first ten drugs took effect Jan. 1, 2026. The paper notes that generic versions of dapagliflozin, sacubitril-valsartan and ticagrelor reached plan formularies in the same years negotiation began. AB-rated generic Entresto launched July 22, 2025, from Novadoz (MSN), followed July 24, 2025, by Torrent.
CMS set the negotiated Entresto price at $295 for a 30-day supply, alongside $231 for Eliquis, $197 for Xarelto and $197 for Jardiance. Against Entresto’s 2023 list price of $628, $295 is a 53% discount. Cost Plus Drugs listed 30-day generic sacubitril-valsartan at $62.50, 90% below that list price, according to a Leerink analysis from Aug. 5, 2025.
A negotiated price lowers what Medicare pays, but a patient’s share depends on plan design. DLA Piper’s analysis found that about 90% of stand-alone Part D formularies charge coinsurance, a percentage of the drug’s price, rather than a flat copay for non-specialty selected drugs. Patients on flat copays, and those on Low-Income Subsidy, see little or no change from the negotiated price. In 2026, Part D caps out-of-pocket spending at $2,100, so patients who hit the cap gain nothing from a lower price.
The authors call the pattern “a potential missed opportunity for drug selection and timeliness.” They note that eligibility begins at least seven years after approval and negotiation can take more than two years, while patent exclusivity typically lasts 12 to 16 years. At least four of the ten first-round drugs already had generics.
CMS projected about $1.5 billion in aggregate out-of-pocket savings in 2026 for about nine million people using at least one of the ten drugs, CMS officials said. Economists Lederman, Olssen and Pauly reached a different conclusion in an NBER working paper: most users of targeted drugs face no change or even higher marginal cost sharing.
An Annals of Internal Medicine research letter from Castle and Huskamp found 26% to 42% savings in Medicare Advantage drug plans and 33% to 49% in stand-alone plans for six drugs below the cap. Users of Stelara, Imbruvica and Enbrel reached the $2,100 cap and saw no direct savings from lower prices, the same letter reported. DLA Piper estimates that about 11% of selected-drug users outside the Low-Income Subsidy in coinsurance plans may save in 2026, falling to about 6% in 2027.
The timing problem sits at the center of a policy fight. Under current rules, small-molecule drugs become eligible for negotiation seven years after approval while biologics wait 11, a gap supporters of change call the “pill penalty.” An analysis by Vital Transformation, cited by We Work For Health, says small-molecule research investment fell “by as much as 70%.”
The EPIC Act, introduced by Rep. Greg Murphy as H.R. 1492 and in the Senate as Sen. Thom Tillis’s S. 832, would raise the small-molecule eligibility window from seven to 11 years starting with the 2028 price year.
Critics argue the change would shrink the program. Public Citizen found that six of eight small-molecule drugs in the third negotiation round would have been excluded under EPIC. KFF’s analysis of a four-year delay found 13 of 25 drugs in rounds one and two would have been ineligible. The NYU finding points to a different timing problem: the program may reach some drugs after generics have already cut prices.
The Supreme Court denied six industry petitions challenging the program May 18, 2026.
Negotiated prices do not last once a generic reaches the market. Under the program’s “bona fide marketing” standard, CMS stops applying a negotiated price when a generic or biosimilar is marketed. The National Community Pharmacists Association says Entresto, Stelara and Xarelto are scheduled to leave the program Jan. 1, 2027. Readers should confirm the list with CMS.
The paper places rivaroxaban in its no-generic group, a classification that sits uneasily with the scheduled Xarelto exit, and the study does not resolve that tension.
Eliquis faces the same clock. Pfizer and Bristol-Myers Squibb said in 2021 that generic apixaban cannot launch before April 1, 2028, subject to appeals. If generics launch on that date, Eliquis’s $231 negotiated price would last about 27 months. Round-three prices, due Nov. 30, take effect Jan. 1, 2028.
The findings describe associations, not proven causes. The data cover only the first year of negotiated prices, and difference-in-differences designs depend on treated and comparison drugs following similar trends before the policy and on no other policy changes affecting them. When a plan covered more than one drug in a therapeutic class, the figure used the lowest-cost option. The study was funded by the American Heart Association, the National Heart, Lung, and Blood Institute and an NYU Department of Medicine award.
Cost matters because it shapes whether patients keep taking medicine. A 2020 CDC analysis by Van Alsten and Harris linked cost-related nonadherence to 15% higher all-cause mortality among adults with cardiovascular disease. A March 2026 JACC analysis presented at ACC.26 found nonadherence among seniors with heart disease fell 2.1 points overall, and 5.5 points in a low-income subgroup newly eligible for subsidies, after Inflation Reduction Act provisions took effect.
Open Enrollment runs through Dec. 7. Readers can ask a pharmacist or prescriber whether an AB-rated generic exists, check each plan’s formulary for whether it charges coinsurance or a copay, and compare costs for the generic and brand versions.
Negotiated prices lowered heart-drug costs most where no generic competitor existed, and the same program will drop those prices once generics arrive. For patients, the safest plan is to treat the negotiated price as one of several tools: confirm whether a generic exists, check the plan’s cost-sharing design and watch the $2,100 cap.
AB-rated generic sacubitril-valsartan launched in July 2025 from Novadoz and Torrent. Your cost depends on your plan’s formulary tier and whether it charges coinsurance or a copay, so check both the brand and generic prices before December 7.
Pfizer and Bristol-Myers Squibb said in 2021 it cannot launch before April 1, 2028, and appeals could change that.
Yes. Under the bona fide marketing standard, CMS stops applying the negotiated price once a generic is marketed, and the National Community Pharmacists Association says Entresto, Stelara and Xarelto are scheduled to exit Jan. 1, 2027.
Savings go mainly to patients in coinsurance plans who take drugs priced above generic alternatives and who stay below the $2,100 cap. Flat-copay and Low-Income Subsidy enrollees see little change, DLA Piper’s analysis found, and patients at the cap saw no direct savings.